IBB iShares Biotechnology ETF Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
14:40
Jul 17
Jul 17
Rotation into healthcare, financials, biotech.
A whole bunch of places are trying to catch up after being ignored in favor of AI. There is big interest in healthcare, financials, and biotechs, with early stage companies getting bought. Money may rotate back into these laggards. Cash flow companies that thrive without depending on one spending track look compelling.
MED
04:00
Jul 10
Jul 10
Use biotech ETF for safer exposure.
Individual investors, especially beginners, should avoid picking biotech stocks directly and instead use a biotech ETF like the Bio Top 10 ETF for safer exposure to the sector.
MED
14:49
Jul 09
Jul 09
Biotech wins from M&A and AI.
Biotech benefits from strong M&A activity and the adoption of AI to accelerate drug discovery. It offers a dual play on the M&A theme and the AI theme.
MED
23:08
Jul 07
Jul 07
US biotech rally signals peak rates; buy
The US biotechnology index is hitting all-time highs despite rising market interest rates. This rally suggests the market is pricing in a peak in rates, anticipating that rates will decline. Biotech breaking out acts as a leading signal for lower rates, making the sector attractive.
MED
21:03
Jul 02
Jul 02
IBB chart unreal, missed huge move
IBB (biotech ETF) has an unreal chart and should have been the trade he took. The missed breakout shows strong momentum and he regrets not being in it.
MED
02:20
Jul 02
Jul 02
Aggressive Nasdaq biotech ETF for upside
TIGER US Nasdaq Bio ETF is an aggressive biotech vehicle similar to the US-listed IBB. It holds a mix of large and mid‑small biotech names with significant exposure to GLP-1 and other innovative pipelines, aiming for faster upside. It suits investors willing to accept higher volatility for greater return potential.
MED
00:38
Jun 27
Jun 27
IBB breakout driven by broad biotech strength.
The IBB biotech ETF has broken out to the upside with a strong chart, and the rally is broad-based, not driven solely by large component Eli Lilly, indicating genuine rotation into biotech and providing a clear buy signal.
MED
21:06
Jun 26
Jun 26
IBB biotech breakout looks strong
The IBB biotech ETF just printed a textbook breakout above resistance with a clean 5% move. The chart is 'nuts' and not driven solely by Eli Lilly, which is only ~1% of the index. This suggests broad-based momentum in biotech, making it an attractive breakout buy.
MED
00:49
Jun 26
Jun 26
US biotech rally, diversify from Korea
While Korean biotech stocks are struggling under extreme semiconductor concentration, US biotech and healthcare sectors are showing strong relative strength with IBB and XBI hitting new highs. Investors should consider diversifying globally into US biotech ETFs to participate in this trend.
MED
23:43
Jun 24
Jun 24
IBB chart looks amazing
The IBB biotech ETF chart looks the best in the market, with an unbelievable technical setup, suggesting a strong bullish breakout in biotech.
MED
21:38
Jun 24
Jun 24
Biotech IBB is strong buy
The biotechnology sector (IBB) is showing the strongest chart in the market, breaking out and looking 'unbelievable', making it a buy even though he missed the initial move.
MED
02:41
Jun 24
Jun 24
US biotech rally on M&A safety play.
US biotech ETFs XBI and IBB are making 52-week highs, driven by aggressive large pharma M&A activity that acts as a safety play despite elevated interest rates. The M&A momentum and defensive characteristics are attracting flows, while Korean biotech lags.
HIGH
23:38
Jun 22
Jun 22
IBB breakout after long consolidation
The biotech ETF IBB is about to break out of a 204‑day consolidation pattern. The chart looks exceptionally strong, and he has seen smart money positioning long biotech names. He is long the sector.
MED
03:18
Jun 15
Jun 15
Oil drop triggers biotech rotation
With oil prices likely to break below $80 within 2-3 months and the peace deal easing inflation fears, biotech and healthcare will see a return of buying interest. The pattern resembles mid-2022 when falling oil triggered an IBB (US biotech ETF) rally, and Korean biotech stocks will similarly benefit from lower rates and flows rotating out of crowded semiconductor positions.
MED
02:39
Jun 15
Jun 15
Oil decline to trigger US healthcare ETF rebound
Oil price peaks historically marked the bottom for healthcare stocks; in 2022, IBB rebounded after oil topped. With oil now entering a structural decline, US healthcare ETFs like IBB are setting up for a new recovery cycle.
MED
00:23
Jun 10
Jun 10
AI-driven biotech renaissance benefits IBB
Biotechnology and drug discovery are secular mega-trends being accelerated by AI (e.g., Claude Fable's 10x speedup in protein design). The iShares Biotechnology ETF (IBB) is the best gainer on the watchlist, and the speaker sees bio trades as attractive long-term holds among the 'long-term social trends' he believes in.
MED
05:38
Jun 05
Jun 05
Long IBB on breakout from consolidation.
The biotech ETF IBB is about to break out of a 2,000-day consolidation, with AI drug discovery as a catalyst. He sees momentum from early trend-spotters and positive price action.
MED
22:02
Jun 04
Jun 04
Biotech breakout, AI high beta
Biotech ETF IBB is about to break out of a 20,000-day consolidation, fueled by AI-driven drug discovery and high beta potential. He sees it as a primed narrative.
HIGH
11:30
Jun 02
Jun 02
Buy large-cap pharma/biotech on KOSDAQ
Pharmaceutical and biotechnology stocks, specifically those in the top 50 by market cap on KOSDAQ, are currently buyable. The speaker expects a meaningful rebound in the sector within June and notes that these stocks have been oversold while earnings are not necessarily weak.
MED
22:13
Apr 22
Apr 22
Invest in infrastructure, renewables, defense, AI.
Infrastructure, renewable energy, nuclear power, nearshoring, AI in education and health, biome technology, and defense are high-conviction investment areas due to the war, energy security concerns, and technological advancements, as these sectors will see increased demand and investment.
HIGH
21:00
Apr 07
Apr 07
Speaker presents charts showing the Biotech ETFs (XBI - equal-weighted, IBB - cap-weighted) are "acting great technically" and consolidating, with the XBI/IBB ratio suggesting further relative upside for XBI. The improving technical posture, after a prolonged period of weakness, indicates building momentum and a potential breakout. LONG on biotech ETFs, with a preference for the equal-weighted XBI based on the ratio chart. A broader market sell-off negating the sector's technical strength.
21:07
Mar 16
Mar 16
"we went from by far the most expensive drugs anywhere in the world prescription drugs to the least expensive... Your drug prices are going to be dropping at levels never even by 50, 60, 70, 80% in some cases." The President claims to have successfully implemented a "Most Favored Nations" drug pricing policy, drastically reducing U.S. drug prices. If this is accurately reflected in policy, it would create severe top-line pressure on pharmaceutical and biotechnology companies, compressing margins and negatively impacting earnings. AVOID the healthcare and biotech sectors due to asserted government price controls. The policy's implementation or impact may be less severe than described; innovation pipelines could offset pricing pressure.
19:31
Mar 11
Mar 11
You have the large pharmaceutical companies which have these patent cliffs coming off. They're going to lose exclusivity and they need to fill that pipeline... they have an exceeding amount of financial ability and capital to do that. Big Pharma is facing an existential revenue threat as blockbuster drugs lose patent protection. Armed with massive cash reserves, they will be forced to aggressively acquire small and mid-cap biotech companies—specifically in oncology, immunology, and cardiometabolic spaces—to buy innovation, driving up valuations across the entire biotech sector. LONG. A target-rich environment combined with desperate, cash-rich buyers will create significant buyout premiums for innovative biotech firms. Increased FTC antitrust scrutiny could chill mega-mergers, or high-profile clinical trial failures could reduce the pool of viable acquisition targets.
15:01
Feb 06
Feb 06
Biotech is the most uncorrelated sector with the highest dispersion. 70% of unprofitable biotechs lose money, but the sector has experienced a massive drawdown (historically followed by massive recoveries). The "baby has been thrown out with the bathwater." A systematic approach filtering for "Quality" (owned by specialists) and "Value" (low Market Cap relative to R&D Spend) identifies winners in a sector where generalist capital has fled. LONG. The sector offers "lottery ticket" positive skewness after a deep cyclical bottom. High failure rate of individual clinical trials; interest rate sensitivity for unprofitable companies.
About IBB Analyst Coverage
Buzzberg tracks IBB (iShares Biotechnology ETF) across 7 sources. 22 bullish vs 0 bearish calls from 15 analysts. Sentiment: predominantly bullish (92%). 24 total trade ideas tracked. Past 7 days: 1 bullish. Latest voices: Sarah Hunt, Lee Kwon-hee, Michelle Weaver.